National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Population
Patients with suspected or confirmed acute coronary syndrome, including ST-elevation myocardial infarction…
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
Adopt serial troponin testing for MI diagnosis and ACS risk stratification; codifies troponin as the reference biomarker in laboratory guidelines.
Key Points
- To provide evidence-based laboratory medicine practice guidelines on the optimal selection, analytical performance, sampling intervals, and clinical interpretation of biochemical markers for acute coronary syndromes.
- Synthesized clinical and laboratory trial evidence through the National Academy of Clinical Biochemistry to establish diagnostic and prognostic recommendations.
- Evaluated biomarkers of myocardial necrosis (cardiac troponins, CK-MB, myoglobin), hemodynamic stress (natriuretic peptides), inflammation (hs-CRP), and ischemia across STEMI and NSTEACS presentations.
- Designated cardiac troponin (I or T) as the preferred biomarker for detecting myocardial necrosis and risk stratification, recommending serial sampling at presentation and 6 to 9 hours later.
- Demonstrated that elevated baseline troponin levels independently predict death and recurrent ischemic complications, identifying high-risk patients who gain therapeutic benefit from early invasive management and potent antiplatelet therapies.
- Determined that multimarker strategies incorporating natriuretic peptides and inflammatory markers offer additive prognostic information for heart failure and mortality, though management decisions should not rely solely on them.
Structured PICO
P
Population
Patients with suspected or confirmed acute coronary syndrome (ACS), including ST-elevation myocardial infarction (STEMI) and non-ST elevation ACS (NSTEACS), presenting with nontraumatic chest symptoms.
I
Intervention
Utilization of biochemical markers (including cardiac troponin, natriuretic peptides, and markers of inflammation and ischemia) for initial evaluation, diagnosis, early risk stratification, and management.
These guidelines establish the central role of cardiac biomarkers, particularly cardiac troponin, in the diagnosis, risk stratification, and management of acute coronary syndromes.
Cite This Study
Morrow et al. (2007) studied this question.